By Dr. Corina Ianculovici, DNP, FAAMFM, ABAAM-HP, AGNP
Founder & Clinical Director, Mirelle Institute for Longevity & Regenerative Medicine

Cellular Medicine Association - Faculty

For decades, erectile dysfunction has often been approached as though it were an isolated problem of the penis.

A man reports difficulty achieving or maintaining an erection. Testosterone is checked. Sildenafil or tadalafil is prescribed. If the medication works, the problem may be considered adequately addressed.

But erectile function is far more complex.

Normal erection requires coordinated interaction among the cardiovascular system, vascular endothelium, nitric-oxide signaling, autonomic and peripheral nerves, cavernosal smooth muscle, hormonal signaling, pelvic-floor musculature, metabolic health, and psychological state.

In my work in functional, regenerative, and longevity medicine—and in my role as a Cellular Medicine Association Faculty Trainer—I believe one of the most important shifts in modern men's sexual health is moving away from treating erectile dysfunction as an isolated symptom and toward understanding the physiology that created the dysfunction.

Instead of asking only:

“What can we give this patient to produce an erection?”

we should also be asking:

“Why has his erectile physiology deteriorated?”

That question forms the foundation of what I call the Modern ED Regenerative Approach.

Erectile Dysfunction Is Often a Systems Problem

An erection is fundamentally a neurovascular event.

Sexual stimulation initiates neural signaling that promotes nitric-oxide release. Penile vascular smooth muscle relaxes, arterial inflow increases, the corpora cavernosa expand, and venous outflow becomes restricted sufficiently to maintain rigidity.

Disruption anywhere along that pathway may impair erectile function.

Cardiovascular disease can reduce arterial inflow.

Diabetes may injure both blood vessels and peripheral nerves.

Insulin resistance, obesity, inflammation, and metabolic dysfunction may impair endothelial signaling.

Pelvic surgery can damage autonomic nerves.

Hormonal deficiency can reduce libido, nitric-oxide signaling, and tissue responsiveness.

Structural fibrosis may impair cavernosal expansion.

Certain medications can interfere with sexual response.

Anxiety, depression, stress, performance concerns, and relationship factors may further compound an underlying organic problem.

This is why many men do not have a single “cause” of ED.

A patient may simultaneously have:

vascular dysfunction + insulin resistance + declining testosterone + pelvic-floor weakness + medication effects.

Treating only one component may therefore produce an incomplete response.

Erectile Dysfunction May Be a Cardiovascular Warning Sign

One of the most important developments in modern sexual medicine is the recognition that erectile dysfunction may be a marker of systemic vascular disease.

The penile circulation depends heavily upon endothelial health.

Many of the processes associated with coronary artery disease are also associated with erectile dysfunction:

• hypertension;
• diabetes;
• insulin resistance;
• dyslipidemia;
• obesity;
• smoking;
• sedentary lifestyle;
• chronic inflammation;
• and endothelial dysfunction.

The Princeton IV Consensus emphasizes that men presenting with erectile dysfunction—particularly suspected vasculogenic ED—should be evaluated with cardiovascular risk in mind.

This changes the clinical significance of the complaint.

For some men, ED is not simply a sexual-health inconvenience.

It may be one of the earliest clinically visible manifestations of systemic endothelial dysfunction.

A visit for erectile dysfunction may therefore create an opportunity to identify previously unrecognized:

• hypertension;
• diabetes;
• metabolic syndrome;
• dyslipidemia;
• obesity-related vascular risk;
• or subclinical cardiovascular disease.

That is why I consider cardiovascular assessment an essential component of modern ED care.

Step One: Measure the Dysfunction

Before treating ED, establish a baseline.

Validated questionnaires such as the International Index of Erectile Function (IIEF) and the shorter IIEF-5/SHIM — Sexual Health Inventory for Men allow us to quantify erectile dysfunction rather than relying exclusively on subjective impressions.

This becomes especially important when multiple interventions are being considered.

If a patient undergoes:

• cardiovascular optimization;
• hormonal treatment;
• medication adjustment;
• pelvic-floor rehabilitation;
• P-Shot® therapy;
• or combination treatment,

we need an objective way to assess whether erectile function has actually improved.

The clinical history should also address:

• onset and duration;
• morning erections;
• spontaneous erections;
• rigidity;
• ability to maintain erection;
• libido;
• ejaculation;
• orgasm;
• penile curvature;
• penile pain;
• response to PDE5 inhibitors;
• history of prostate or pelvic surgery;
• neurologic disease;
• medications;
• smoking;
• alcohol;
• sleep quality;
• and psychological contributors.

Good regenerative medicine begins with good diagnosis.

Step Two: Perform a Functional Cardiovascular and Metabolic Evaluation

When a man presents with ED, I do not want to know only whether he can achieve an erection.

I want to know what is happening to the vascular system responsible for creating it.

A comprehensive evaluation may include:

• blood pressure;
• heart rate;
• waist circumference and body composition;
• fasting glucose and/or HbA1c;
• lipid profile;
• smoking history;
• exercise tolerance;
• sleep-apnea risk;
• insulin resistance;
• obesity;
• family cardiovascular history;
• medication review;
• and overall cardiovascular risk.

For appropriate patients, formal ASCVD cardiovascular risk assessment may be helpful.

Men with concerning symptoms, poor exercise tolerance, significant vascular risk, or an uncertain cardiovascular profile may require further evaluation or cardiology involvement before elective ED treatment.

Selected patients may also warrant additional cardiovascular risk stratification, including coronary artery calcium evaluation when clinically appropriate.

This is what I mean by a functional cardiovascular ED evaluation.

We are not simply asking:

“Is blood reaching the penis?”

We are asking:

“What is the health of the vascular system responsible for supplying it?”

Step Three: Evaluate the Hormonal Environment

Testosterone matters.

But testosterone is not synonymous with erectile function.

Testosterone contributes to:

• libido;
• sexual motivation;
• nitric-oxide signaling;
• central arousal;
• tissue maintenance;
• and sexual responsiveness.

Men with true hypogonadism should therefore be identified and appropriately treated.

A comprehensive male hormonal evaluation may include, depending upon presentation:

• morning total testosterone;
• free testosterone;
• SHBG;
• LH;
• FSH;
• prolactin;
• thyroid function;
• estradiol in selected patients;
• and appropriate hematologic and prostate monitoring when testosterone therapy is being considered.

But one of the most important concepts I discuss with men is this:

Testosterone optimization does not automatically restore erectile function.

A patient can have an excellent testosterone level and still have severe ED.

Why?

Because testosterone cannot automatically reverse:

• atherosclerosis;
• arterial insufficiency;
• diabetic neuropathy;
• cavernosal fibrosis;
• pelvic nerve injury;
• severe endothelial dysfunction;
• or pelvic-floor dysfunction.

The TRAVERSE Sexual Function Study illustrates this distinction well. Testosterone therapy in hypogonadal men improved sexual activity, sexual desire, and symptoms of androgen deficiency, but did not produce a significant improvement in erectile function compared with placebo.

That does not mean testosterone is unimportant.

It means testosterone alone may not be sufficient.

Hormonal optimization supports one component of the erectile system.

Vascular integrity, neural signaling, erectile-tissue health, and pelvic-floor function remain equally important.

Step Four: Treat the Cardiovascular and Metabolic Terrain

Patients are often understandably interested in the newest procedure.

But sometimes the most important regenerative intervention begins long before an injection.

A patient with:

• poorly controlled diabetes;
• severe insulin resistance;
• obesity;
• uncontrolled hypertension;
• dyslipidemia;
• chronic inflammation;
• smoking exposure;
• or severe physical deconditioning

has a very different regenerative environment from a metabolically healthy patient.

These factors influence:

• endothelial health;
• microvascular circulation;
• nitric-oxide signaling;
• tissue repair;
• inflammation;
• and treatment responsiveness.

Lifestyle and cardiovascular risk-factor modification should therefore occur alongside ED-specific treatment.

This does not mean withholding conventional therapy.

PDE5 inhibitors such as sildenafil and tadalafil remain important and effective treatments for many men.

The goal is not to abandon evidence-based medication.

The goal is to avoid mistaking symptom control for correction of the underlying physiology.

Step Five: Where Does the P-Shot® Fit?

The P-Shot®, invented by Charles Runels, MD, represents a platelet-based regenerative approach to male sexual function.

Platelet-rich plasma contains concentrated platelets capable of releasing signaling molecules involved in tissue repair and regeneration, including:

• VEGF;
• PDGF;
• IGF-1;
• EGF;
• FGF;
• and other bioactive mediators.

These signaling molecules participate in biologic processes associated with:

• angiogenesis;
• endothelial signaling;
• extracellular-matrix remodeling;
• tissue repair;
• and cellular regeneration.

The concept behind platelet-based penile therapy is fundamentally different from that of a PDE5 inhibitor.

A PDE5 inhibitor temporarily enhances the biochemical pathway necessary for erection.

Platelet-based regenerative therapy attempts to influence the local tissue environment itself.

That is an important conceptual distinction.

PRP, PRFM and the Regenerative Rationale

In platelet-based regenerative protocols, the biologic product begins as platelet-rich plasma.

When PRP is activated with calcium chloride, fibrinogen begins converting to fibrin and the product transitions toward a platelet-rich fibrin matrix, or PRFM.

This creates a developing fibrin scaffold capable of helping localize platelets and their signaling molecules within treated tissue.

From a regenerative perspective, this approach is intended to support local:

• endothelial biology;
• tissue remodeling;
• angiogenic signaling;
• smooth-muscle health;
• and neurovascular repair mechanisms.

However, biologic plausibility is not the same thing as definitive clinical proof.

That distinction is essential.

What Does the Clinical Evidence for Penile PRP Show?

Published research on intracavernosal PRP for erectile dysfunction is promising—but mixed.

A randomized placebo-controlled trial by Poulios and colleagues studied men with mild-to-moderate vasculogenic ED. At six months, a substantially greater proportion of PRP-treated men achieved a clinically meaningful improvement in erectile-function scores compared with placebo.

Other controlled studies have also reported improvement.

However, not every randomized study has demonstrated superiority over placebo.

A 2023 randomized, double-blind placebo-controlled study by Masterson and colleagues found PRP to be well tolerated but did not demonstrate a significant efficacy advantage over placebo in the studied population.

This difference between studies is important.

Clinical trials vary significantly in:

• platelet concentration;
• PRP preparation;
• activation;
• injection protocol;
• patient selection;
• treatment frequency;
• and outcome measurements.

For that reason, current major urologic guidelines continue to consider penile PRP investigational rather than established first-line ED therapy.

That is the responsible way to present the evidence.

PRP Research Is Not Automatically Evidence for Every P-Shot® Protocol

 Another distinction is frequently overlooked.

Most published clinical trials investigate PRP.

They do not necessarily evaluate every branded P-Shot® preparation, platelet concentration, calcium-chloride activation protocol, PRFM method, injection pattern, or treatment schedule.

Therefore, evidence supporting PRP should not be automatically interpreted as proving every variation of a platelet-based penile procedure.

Informed consent should make this distinction clear.

At the same time, the developing research surrounding platelet biology, angiogenic signaling, endothelial repair, and penile tissue regeneration provides an important scientific basis for continued investigation.

Step Six: The Frequently Overlooked Component — The Male Pelvic Floor

The penis does not function independently from the pelvis.

Pelvic-floor muscles contribute mechanically to:

• erectile rigidity;
• ejaculation;
• urinary continence;
• pelvic stability;
• and sexual function.

The ischiocavernosus and bulbospongiosus muscles are particularly important.

Their contraction contributes to intracavernosal pressure and assists in maintaining the rigid phase of erection.

This means a man may have reasonable arterial inflow while still having compromised erectile mechanics because pelvic-floor recruitment is inadequate.

Pelvic-floor rehabilitation therefore deserves a meaningful role in ED care.

One randomized controlled trial evaluating pelvic-floor exercises with biofeedback in men with ED found that after six months:

• 40% regained normal erectile function;
• another 35.5% improved;
• and 24.5% did not improve.

The pelvic floor is not simply relevant to continence.

It is part of erectile physiology.

Step Seven: Where Emsella® May Fit

Emsella® uses high-intensity focused electromagnetic stimulation to produce repeated pelvic-floor muscle contractions.

From my clinical perspective, its role within a comprehensive male sexual-health program is best understood as:

pelvic-floor neuromuscular rehabilitation and re-education.

It is not a replacement for cardiovascular treatment.

It is not a replacement for hormonal evaluation.

And it is not a substitute for appropriate ED medication or urologic treatment.

It addresses another physiologic component of erectile function.

The Importance of Neuromuscular Re-Education

Strength alone does not determine muscular function.

A muscle must also be appropriately recruited and coordinated by the nervous system.

Repeated electromagnetic stimulation recruits pelvic-floor musculature during the treatment session and may support:

• muscle recruitment;
• strength;
• endurance;
• coordination;
• neuromuscular re-education;
• continence;
• and the muscular contribution to erectile rigidity.

This is particularly relevant in men following prostate surgery, where pelvic-floor function, continence, and sexual function may all be affected.

Clinical research investigating electromagnetic pelvic-floor stimulation after prostatectomy has reported improvements in pelvic-floor-related outcomes, particularly urinary continence, with sexual-function research continuing to evolve.

Repeated Muscle Contraction and Regional Pelvic Perfusion

There is another physiologic component that deserves attention.

When skeletal muscle repeatedly contracts, its metabolic demand increases.

The body responds by increasing blood flow to the active muscle.

This is basic exercise physiology.

Repeated pelvic-floor contraction therefore creates a physiologic mechanism for increasing local muscular blood flow and regional pelvic tissue perfusion during activation.

This is relevant because erectile function itself is highly dependent upon vascular health.

The pelvic floor exists within the same regional vascular environment supporting the:

• penis;
• perineum;
• surrounding pelvic musculature;
• prostate;
• and other pelvic structures.

For this reason, repeated selective pelvic-floor contraction may support regional pelvic circulation and tissue perfusion while simultaneously promoting neuromuscular rehabilitation.

It is important, however, to use precise language.

At present, I would not claim that Emsella® has conclusively been shown to increase intraprostatic blood flow specifically.

Direct prostate-gland perfusion has not been adequately established in controlled human studies.

The more scientifically appropriate description is:

Repeated pelvic-floor muscular contraction increases muscular metabolic activity and supports increased local blood flow and regional pelvic tissue perfusion.

This provides a physiologic rationale without overstating current evidence.

Why Emsella® and the P-Shot® Address Different Parts of Erectile Physiology

This is where a systems-based regenerative model becomes especially valuable.

The treatments are not competitors.

They address different physiologic targets.

Cardiovascular and metabolic optimization

Targets:

• systemic vascular health;
• endothelial function;
• arterial supply;
• inflammation;
• metabolic disease.

Hormonal optimization

Targets:

• endocrine signaling;
• libido;
• nitric-oxide support;
• androgen deficiency;
• tissue responsiveness.

P-Shot® / PRP-PRFM

Targets the local regenerative environment, with the intent of supporting:

• endothelial signaling;
• tissue repair;
• extracellular-matrix remodeling;
• neurovascular biology;
• and regenerative signaling.

Emsella®

Targets:

• pelvic-floor recruitment;
• muscular strength;
• neuromuscular coordination;
• pelvic-floor re-education;
• and increased regional blood flow associated with repetitive muscular contraction.

An erection depends upon all of these systems interacting.

That is why ED treatment should rarely be reduced to a single modality.

The Mirelle Method® Four-Pillar Model of the

Modern ED Regenerative Approach

I organize this approach around four interconnected physiologic pillars.

Pillar 1: Vascular and Metabolic Health

Evaluate and optimize:

• blood pressure;
• endothelial health;
• glucose metabolism;
• insulin sensitivity;
• lipids;
• cardiovascular risk;
• smoking;
• obesity;
• exercise;
• sleep;
• and systemic inflammation.

Pillar 2: Hormonal Signaling

Evaluate:

• testosterone;
• free testosterone;
• SHBG;
• LH/FSH when appropriate;
• prolactin;
• thyroid status;
• and selected additional endocrine markers.

The goal is to identify true hormonal dysfunction—not automatically attribute ED to testosterone.

Pillar 3: Local Regenerative Biology

In appropriately evaluated and fully informed patients, platelet-based regenerative strategies may be considered as an adjunct intended to influence local tissue biology.

The evidence is evolving and should be discussed transparently.

Pillar 4: Pelvic-Floor Neuromuscular Function and Regional Circulation

Pelvic-floor rehabilitation may address:

• muscular recruitment;
• strength;
• neuromuscular coordination;
• erectile mechanical support;
• continence;
• and regional pelvic blood flow associated with repeated contraction.

Many patients have dysfunction in more than one pillar.

That is precisely why combination treatment can make physiologic sense.

What About PDE5 Inhibitors?

A regenerative philosophy should never become an anti-medication philosophy.

Sildenafil, tadalafil, and related PDE5 inhibitors remain highly useful and evidence-based therapies.

The goal is integration.

A patient may benefit from tadalafil and cardiovascular optimization.

Another may need testosterone because he has documented androgen deficiency and require vascular treatment.

Another may benefit from pelvic-floor rehabilitation while continuing medication.

An appropriately selected and informed patient may choose platelet-based regenerative treatment while also addressing cardiometabolic disease.

The question should not be:

“Which one treatment is best?”

The better question is:

“Which physiologic systems are failing in this particular patient?”

When Advanced Erectile Testing Is Appropriate

Not every man requires every diagnostic study.

But some patients require more than routine laboratory testing.

When significant vasculogenic disease is suspected, penile duplex Doppler ultrasound can provide valuable information about penile arterial inflow and veno-occlusive function.

Selected patients may also require:

• cardiovascular testing;
• specialized endocrine evaluation;
• urologic evaluation;
• nocturnal erection testing;
• neurologic assessment;
• or psychosexual evaluation.

Precision medicine means testing when the result will change the treatment strategy—not performing unnecessary testing on every patient.

Erectile Dysfunction Is a Symptom. Find the Biology Behind It.

The most important point I want men and clinicians to understand is that ED is not automatically an inevitable consequence of aging.

Nor is it automatically a testosterone problem.

For one patient, ED may represent endothelial dysfunction.

For another, occult cardiovascular disease.

For another, insulin resistance.

For another, hypogonadism.

For another, diabetic neuropathy.

For another, pelvic nerve injury following prostate surgery.

For another, pelvic-floor dysfunction.

And for many men, several of these mechanisms coexist.

This explains why:

1. testosterone alone may fail;
2. PDE5 inhibitors may fail;
3. PRP alone may fail;
4. pelvic-floor treatment alone may fail.

Each treatment has a physiologic target.

Each treatment also has limitations.

PRP cannot overcome end-stage vascular disease.

Testosterone cannot repair major nerve injury.

A PDE5 inhibitor cannot rehabilitate a dysfunctional pelvic floor.

Emsella® cannot reverse advanced cavernosal fibrosis.

Successful treatment begins by understanding which systems are impaired.

The Future of ED Care Is Precision Integration

Modern erectile-dysfunction care should move beyond:

ED → prescription.

A more sophisticated approach is:

ED → quantify severity → identify the dominant physiology → evaluate cardiovascular risk → assess metabolic health → evaluate hormones → assess structural and neurologic factors → address the pelvic floor → treat symptoms → selectively integrate regenerative therapies → objectively measure outcomes.

That is the foundation of the Modern ED Regenerative Approach.

It brings together:

• cardiovascular medicine
• functional and metabolic medicine
• hormonal optimization
• regenerative medicine
• pelvic-floor neuromuscular rehabilitation

into one coherent clinical strategy.

And that is the conversation we will continue in the upcoming Modern ED Regenerative Approach podcast series.

Clinical Evidence Supporting This Discussion

Princeton IV Consensus Recommendations, 2024 — Positions erectile dysfunction as an important cardiovascular risk marker and expands cardiovascular risk stratification in men presenting with ED, including selective coronary artery calcium assessment.

European Association of Urology Guidelines on Erectile Dysfunction — Supports comprehensive history, validated ED measurement, cardiovascular and metabolic assessment, morning testosterone testing, lifestyle modification and conventional ED therapy; currently regards intracavernosal PRP evidence as insufficient for routine clinical recommendation.

Pencina et al., TRAVERSE Sexual Function Study — Testosterone treatment in hypogonadal men improved sexual activity, libido and hypogonadal symptoms but did not significantly improve erectile function versus placebo.

Poulios et al., 2021 — Randomized placebo-controlled study in mild-to-moderate vasculogenic ED in which 69% of PRP-treated participants achieved a clinically meaningful improvement at six months compared with 27% of placebo-treated participants.

Masterson et al., 2023 — Randomized double-blind placebo-controlled PRP study demonstrating acceptable tolerability but no significant efficacy advantage over placebo, underscoring uncertainty within the PRP evidence base.

Dorey et al., 2005 — Randomized study of pelvic-floor exercise and biofeedback in men with ED; after six months, 40% regained normal erectile function and an additional 35.5% improved.

Unal et al., 2025 — Randomized quadruple-blind sham-controlled study of magnetic pelvic-floor stimulation following radical prostatectomy showing meaningful improvements in pelvic-floor-related outcomes, while several erectile-function domains did not significantly improve.

Tosun et al., 2025 — Study of high-intensity focused electromagnetic therapy in post-prostatectomy rehabilitation showing improvement in urinary-incontinence severity and reduced pad dependence.

Human Exercise-Hyperemia Research — Demonstrates that contracting skeletal muscle increases local blood flow through metabolic and vasodilatory mechanisms, supporting the physiologic rationale for increased local perfusion during repeated pelvic-floor contraction.

About the Author

Dr. Corina Ianculovici, DNP, FAAMFM, ABAAM-HP, AGNP is the Founder and Clinical Director of the Mirelle Institute for Longevity & Regenerative Medicine and serves as a Cellular Medicine Association Faculty Trainer.

Her clinical and educational work focuses on the integration of functional and metabolic medicine, precision hormone optimization, longevity medicine, regenerative therapies, and advanced sexual-health strategies.

As CMA Faculty, Dr. Ianculovici participates in clinician education surrounding regenerative medicine protocols and emphasizes a systems-based approach in which procedures are integrated with appropriate patient selection, physiologic assessment, hormonal and metabolic optimization, safety, documentation, and longitudinal outcome evaluation.

At Mirelle Institute, her approach to men's sexual health extends beyond symptom management to investigate the cardiovascular, hormonal, metabolic, regenerative, and neuromuscular contributors to sexual function.

Dr. Corina Ianculovici, DNP, FAAMFM, ABAAM-HP, AGNP
CMA Faculty
Founder & Clinical Director of Mirelle Institute for Longevity & Regenerative Medicine
2640 Hwy 70, Building 6B
Manasquan, NJ 08736
732-292-0100

Medical Disclaimer: This article was written by Dr. Corina Ianculovici for educational purposes and does not substitute for individualized medical evaluation, diagnosis, or treatment. Erectile dysfunction may be associated with cardiovascular, endocrine, metabolic, neurologic, urologic, medication-related, or psychological disease. Platelet-based penile therapy remains investigational for erectile dysfunction. Treatment decisions should be individualized following appropriate medical evaluation, informed consent, and discussion of established therapeutic alternatives.